Stock disconnect triggers investor exodus from CStone Pharma
The share price fell nearly 40% in a week after the drugs company was dropped from a scheme allowing mainland investors to trade Hong Kong-listed stocks Key Takeaways: CEO Jason…
FAST NEWS: Brii Bioscience shares rise on favorable hepatitis B data
The latest: Brii Biosciences Ltd. (2137.HK) said Wednesday that a study for its BRII-179 product to treat hepatitis B has shown favorable results in inducing functional immune responses. Looking up: The company…
FAST NEWS: Everest Medicines Hits New Low after New CEO Announcement
The latest: Innovative drug maker Everest Medicines Ltd. (1952.HK) on Monday announced the appointment of Luo Yongqing, formerly president and general manager of Greater China for Brii Biosciences Ltd. (2137.HK),…
Genuine Biotech Seeks IPO Booster from New Oral Covid Drug
Company hopes China’s approval of its small molecule oral Covid-19 drug will draw investors to its newly filed listing plan Key Takeaways: Genuine Biotech has filed to list in Hong…
Booster Shot for Brii Biosciences with First Covid Drug Launch
Brii Biosciences announced the commercial launch of its injectable Covid antibody treatment, which will be covered by government medical insurance in many parts of the country Key Takeaways: The antibody…
Could Covid Drugs Help Cure Financial Ills at Ascletis Pharma?
Ascletis Pharma has applied for U.S. FDA approval to start clinical trials on a new Covid drug, ASC10 Key Takeaways: Ascletis Pharma is ready to put its new Covid drug…
Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field
Global agreement for oral anti-viral comes just months after company signed separate similar tie-up for a Covid mRNA vaccine also in development Key Takeaways Everest has signed a global licensing…
Recent Articles
RELATED ARTICLES
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK -
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
-
Hong Kong’s Café de Coral takes go-slow approach to Mainland dining market
0341.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
